Why Is Fulgent Genetics Stock Moving Higher Today?
Portfolio Pulse from Vandana Singh
Fulgent Genetics Inc (NASDAQ:FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million. The company also reported a Q2 adjusted EPS loss of $(0.08), beating the consensus of $(0.33). Fulgent has raised its FY23 revenue guidance to $260 million, up from the prior guidance of $250 million. FLGT shares are up 1.45% at $40.66 on the last check Friday.
August 04, 2023 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulgent Genetics beat Q2 sales and EPS estimates and raised its FY23 revenue guidance. This positive financial performance is likely to boost investor confidence and could lead to a short-term increase in the stock price.
Fulgent Genetics reported better than expected Q2 results and raised its FY23 revenue guidance. This indicates strong financial performance and future growth potential, which are likely to be viewed positively by investors and could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100